Approval · Notice of Compliance 33438 · 2024
LACOSAMIDE: Notice of Compliance 33438
Issued June 12, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33438
- Date
- June 12, 2024
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- VIMPAT (Ucb Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LACOSAMIDE | 02512874 | Marketed |
| LACOSAMIDE | 02512882 | Marketed |
| LACOSAMIDE | 02512890 | Marketed |
| LACOSAMIDE | 02512904 | Marketed |
Medicinal ingredients
- LACOSAMIDE 50 MG per TAB
- LACOSAMIDE 100 MG per TAB
- LACOSAMIDE 150 MG per TAB
- LACOSAMIDE 200 MG per TAB